Rebamipide Versus Diquafosol and Cyclosporine for Perioperative Dry Eye in Cataract Surgery
Key facts
- Who runs it
- Samsung Medical Center
- Where
- South Korea1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 56 people enrolled
- Started
- 1 Aug 2025
- Ended
- 1 May 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Rebamipide 2% ophthalmic solution
- Diquafosol 3% ophthalmic solution
- Cyclosporine 0.05% ophthalmic solution
- Record updated
- 27 October 2026
Who can take part
- Age
- 40 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Adults scheduled for cataract surgery
- Presence of dry eye disease, defined as an Ocular Surface Disease Index (OSDI) score ≥12 and at least one of the following:; Tear film breakup time (TBUT) ≤7 seconds; Oxford corneal staining grade ≥1; Schirmer's test value ≤10 mm/5 min
- Ability and willingness to comply with the study protocol and follow-up schedule
- Provision of written informed consent
Who cannot take part
- Use of topical intraocular pressure-lowering medications
- Presence of ocular surface or ocular conditions that could affect dry eye status (e.g., active keratitis or ocular infection)
- History of ocular surgery other than cataract surgery in the study eye
- Any systemic or ocular condition judged by the investigator to interfere with study participation or outcome assessment
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this clinical trial is to compare the efficacy of 2% rebamipide monotherapy versus a combination therapy of 3% diquafosol and 0.05% cyclosporine for the management of dry eye disease in patients undergoing cataract surgery. It will also evaluate the safety and ocular surface stability effects of these treatments during the perioperative period.
Read full original descriptionShow less
The main questions it aims to answer are:
Does rebamipide monotherapy maintain tear film breakup time (TBUT) and prevent corneal damage as effectively as the combination therapy after surgery? How do patient symptoms (OSDI scores) and inflammation markers (MMP-9) change with each treatment?
Researchers will compare the rebamipide group to the diquafosol-cyclosporine combination group to evaluate their effects on perioperative dry eye management.
Participants will:
Use the assigned study eye drops starting 1 month before their cataract surgery and continuing for 3 months after surgery.
Visit the clinic for eye examinations at baseline, the day of surgery, and at 1 week, 1 month, and 3 months postoperatively.
Undergo tests including tear film breakup time measurement, corneal staining, Schirmer's test, and tear MMP-9 level assessments.
The 2 groups in the trial
- Group RTreatment being tested
Participants receive topical rebamipide 2% ophthalmic solution four times daily, initiated 1 month before cataract surgery and continued for 3 months postoperatively.
Treatment: Rebamipide 2% ophthalmic solution
- Group DCExisting treatment, for comparison
Participants receive topical diquafosol 3% ophthalmic solution four times daily in combination with cyclosporine 0.05% ophthalmic solution twice daily, initiated 1 month before cataract surgery and continued for 3 months postoperatively.
Treatment: Diquafosol 3% ophthalmic solution and Cyclosporine 0.05% ophthalmic solution
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Rebamipide Versus Diquafosol-Cyclosporine for Perioperative Dry Eye Disease in Cataract Surgery: A Randomized Trial
- Record updated
- 27 October 2026